Switching From Injectable Biologics to ICOTYDE: What Psoriasis Patients Should Know

The approval of ICOTYDE in March 2026 immediately created a question for the millions of psoriasis patients already on injectable biologics: should I switch? The appeal is obvious — replacing injections with a daily pill — but the decision is more nuanced than "pills are easier." This guide covers who should consider switching, how to do it safely, and what trade-offs are involved.

Quick Answer

Switching from injectable biologics to ICOTYDE is safe and reasonable for many patients, but it involves a potential efficacy trade-off. ICOTYDE achieves ~70% PASI 90, while top injectables like Skyrizi (~85%) and Tremfya (~80%) deliver higher clearance. If you are achieving excellent results on your current biologic and tolerate injections, switching may cost you some skin clearance. If you strongly prefer an oral option, the trade-off may be worth it. This is a conversation to have with your dermatologist, not a decision to make alone.

Who Should Consider Switching

Switching to ICOTYDE makes the most sense for patients who:

• Have needle phobia or injection anxiety that causes them to delay or miss doses
• Experience injection site reactions (redness, pain, swelling) with their current biologic
• Travel frequently and find cold-chain storage and injection supplies burdensome
• Are on a biologic with suboptimal results and want to try a different approach
• Have moderate disease where 70% PASI 90 would represent excellent control
• Value daily routine medication over periodic injections

Washout Periods by Current Biologic

Before starting ICOTYDE, you must stop your current biologic and wait for it to clear your system. This "washout" period varies by drug half-life:

Current Biologic	Washout Period	Rationale
Humira (adalimumab)	2–3 weeks	Short half-life (~14 days); clears relatively quickly
Enbrel (etanercept)	1–2 weeks	Shortest half-life among biologics (~3 days)
Cosentyx (secukinumab)	4–8 weeks	Intermediate half-life (~27 days)
Taltz (ixekizumab)	6–8 weeks	Half-life ~13 days but loading doses create depot effect
Tremfya (guselkumab)	8–12 weeks	Long half-life (~17 days with 8-week dosing interval)
Skyrizi (risankizumab)	10–12 weeks	Long half-life; dosed every 12 weeks at steady state
Stelara (ustekinumab)	10–15 weeks	Very long half-life (~21 days with 12-week dosing)

These are general guidelines. Your dermatologist may adjust based on your individual pharmacokinetics, disease severity, and flare risk. Some providers may allow overlap rather than a full washout, particularly for patients at high risk of disease flare.

What to Expect During Transition

The Washout Phase

During the washout period, your biologic is leaving your system but ICOTYDE has not yet kicked in. This is the vulnerable window. Many patients experience some degree of disease flare — return of scaling, redness, itching, or plaque thickening.

Managing the washout:

• Continue topical therapies (corticosteroids, vitamin D analogs, calcineurin inhibitors)
• Moisturize aggressively to maintain skin barrier
• Discuss bridge therapy with your dermatologist (short-course oral steroids or phototherapy in severe cases)
• Monitor for signs of significant flare and contact your provider if symptoms become severe

Starting ICOTYDE

Once the washout is complete, you begin ICOTYDE as a daily oral tablet. Initial response is typically seen within 4–8 weeks, with most patients reaching their best response by Week 16. This is slower than re-starting an injectable biologic but consistent with ICOTYDE's clinical trial timelines.

Months 1–4: Setting Expectations

• Weeks 1–4: Gradual improvement begins. Some patients notice reduced itching and scaling before visible plaque reduction.
• Weeks 4–8: Most patients achieve PASI 50 (50% improvement). Visible plaque thinning and reduced redness.
• Weeks 8–16: Peak response approaches. ~70% of patients achieve PASI 90 by Week 16.

Talking to Your Dermatologist

Bring these questions to your appointment:

1. "Given my current clearance level, what would I realistically gain or lose by switching to ICOTYDE?"
2. "What is the recommended washout period for my specific biologic and dose?"
3. "How will we manage my psoriasis during the washout — do I need bridge therapy?"
4. "Will my insurance cover ICOTYDE, or will I need prior authorization?"
5. "If ICOTYDE doesn't work as well, can I switch back to my current biologic?"
6. "Are there any drug interactions with my other medications?"

A good dermatologist will discuss the trade-offs honestly, not push you toward a specific treatment.

Insurance Considerations

Switching biologics is never just a medical decision — insurance plays a major role:

• New prior authorization required: Even if your current biologic is covered, ICOTYDE requires a separate PA.
• Step therapy may apply: Some plans require documented failure on Otezla or Sotyktu before approving ICOTYDE.
• Specialty tier placement: ICOTYDE may be placed on a specialty tier with higher copays.
• Patient assistance: J&J's Care program offers $0 copay cards for commercially insured patients.
• Switching back: If ICOTYDE doesn't work, getting re-approved for your previous biologic may require another PA and possibly restarting step therapy.

Before switching, ask your insurance to confirm coverage for ICOTYDE and confirm that you can return to your current biologic if needed.

When NOT to Switch

Switching is not appropriate for everyone. Consider staying on your current biologic if:

• You are achieving PASI 90 or better and are satisfied with your results
• You have severe, widespread psoriasis that requires maximum efficacy
• You have a history of severe flares when stopping biologics
• Your insurance creates significant barriers to ICOTYDE coverage
• You have active psoriatic arthritis (ICOTYDE is currently approved only for plaque psoriasis)
• You tolerate your current injections well and prefer less frequent dosing over daily pills

The golden rule: do not sacrifice excellent disease control for convenience unless you have a strong reason to do so.

Timeline and Monitoring

• Before switch: Confirm insurance coverage. Complete TB screening if switching from a non-IL-23 biologic. Get baseline liver function tests.
• Washout period (2–15 weeks): Manage with topicals and bridge therapy as needed.
• Start ICOTYDE: Daily oral tablet. No loading dose required.
• Week 8: First efficacy assessment. Expect PASI 50–75 for most responders.
• Week 16: Full efficacy assessment. If PASI 75 is not achieved, discuss alternatives with your dermatologist.
• Ongoing: No routine lab monitoring required. Continue dermatology follow-up every 3–6 months.

Bottom Line

Switching from injectable biologics to ICOTYDE is a legitimate option for psoriasis patients who want to eliminate injections. The trade-off is real but manageable: ~70% PASI 90 from a pill versus 80–90% from the best injectables. For many patients, that convenience is worth it. For others, maximum clearance matters more.

Use MedSwitcher to check your insurance coverage for ICOTYDE and compare it against your current biologic. Then have an honest conversation with your dermatologist about whether the switch makes sense for your specific situation.